Work

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

Year: 2022
Type: dissertation
Abstract: Simple Summary:The development of biomarkers that can predict the effectiveness of treatments for metastatic castration-resistant prostate cancer (mCRPC) has been a recent challenge.We focused on the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker after enzalutamide administration.A retrospective subgroup analysis and prognostic survey were conducted on 43 patients with mCRPC and bone metastases.The results showed that patients with no detected CTCs at baseline showed significantly longer overall survival (OS) than those with CTCs at baseline.Furthermore, patients who exhibited a negative reversion of CTC status during enzalutamide treatment had significantly longer OS compared to patients with persistent CTC positivity.Achieving CTCnegative reversion during treatment for mCRPC with bone metastases was associated with improved long-term OS.Chronological measurement of CTC status might be clinically useful in the treatment of mCRPC.
Author: 中村, 聡
Institution: Juntendo University
Language: English
Subfield: Cancer Research
Open Access status: green
OpenAlex ID: W6990340067
Cites: 30
Cited by:
Related to: 10